Cipher Pharma (CPHR) Reports Q1 EPS of $0.12
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St futures muted as oil gains curb risk appetite after S&P record close
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- Reddit to join S&P 500 index on Aug. 18, shares leap
Cipher Reports Financial and Operational Results for Q1 2015
May 13, 2015 7:00 AM EDTCompany Achieves Significant Progress Across All Three Components of Growth Strategy
MISSISSAUGA, ON, May 13, 2015 /PRNewswire/ - Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX: CPH) ("Cipher" or "the Company") today announced its financial and operational results for the three months ended March 31, 2015.Â
Highlights for the quarter
Total revenue increased 17% to $9.2 million from $7.9 million in Q1 2014; Strong revenue generated from all three commercialized products: Absorica revenues increased 5% to $6.3 million from $6.0 million in Q1 2014; Epuris revenues were up 139% year-over-year... More